Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period

Elisenda Miró; Ferran Navarro; Beatriz Mirelis; Montserrat Sabaté; Alba Rivera; Pere Coll; Guillem Prats

doi:10.1128/AAC.46.12.3991-3994.2002

Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period

Antimicrob Agents Chemother. 2002 Dec;46(12):3991-4. doi: 10.1128/AAC.46.12.3991-3994.2002.

Authors

Elisenda Miró¹, Ferran Navarro, Beatriz Mirelis, Montserrat Sabaté, Alba Rivera, Pere Coll, Guillem Prats

Affiliation

¹ Departament de Microbiologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma 08025 Barcelona, Spain. emiro@hsp.santpau.es

Abstract

About 7% of 7,252 nonduplicated clinical Escherichia coli strains from a Spanish hospital showed reduced susceptibility to amoxicillin-clavulanate. Of these, 0.37% produced the IRTs TEM-30, TEM-31, TEM-33, TEM-34, TEM-37, TEM-40, TEM-51, and TEM-54; 5.3% were probable class C beta-lactamase overproducers; 0.8% were probable TEM-1 hyperproducers; 0.18% produced OXA-30; 0.15% overexpressed SHV-1; and 0.03% produced a PSE-1 enzyme.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amoxicillin-Potassium Clavulanate Combination / pharmacology*
Drug Resistance, Bacterial / genetics
Electrophoresis, Gel, Pulsed-Field
Escherichia coli / drug effects*
Escherichia coli / enzymology
Escherichia coli / isolation & purification
Humans
Microbial Sensitivity Tests
Phenotype
Spain
beta-Lactamases / genetics*

Substances

Amoxicillin-Potassium Clavulanate Combination
beta-Lactamases